|
1
|
Remon J, Lianes P and Martínez S: Brain
metastases from renal cell carcinoma. Should we change the current
standard? Cancer Treat Rev. 38:249–257. 2012.
|
|
2
|
Salehipoor M, Khezri A, Behzad-Behbahani
A, et al: Role of viruses in renal cell carcinoma. Saudi J Kidney
Dis Transpl. 23:53–57. 2012.
|
|
3
|
Zhao P, Dai M, Chen W and Li N: Cancer
trends in China. Jpn J Clin Oncol. 40:281–285. 2010.
|
|
4
|
Stadler WM: Targeted agents for the
treatment of advanced renal cell carcinoma. Cancer. 104:2323–2333.
2005.
|
|
5
|
Tran HT, Liu Y, Zurita AJ, et al:
Prognostic or predictive plasma cytokines and angiogenic factors
for patients treated with pazopanib for metastatic renal-cell
cancer: a retrospective analysis of phase 2 and phase 3 trials.
Lancet Oncol. 13:827–837. 2012.
|
|
6
|
Nakamoto M and Bergemann AD: Diverse roles
for the Eph family of receptor tyrosine kinases in carcinogenesis.
Microsc Res Tech. 59:58–67. 2002.
|
|
7
|
Andres AC, Reid HH, Zurcher G, Blaschke
RJ, Albrecht D and Ziemiecki A: Expression of two novel eph-related
receptor protein tyrosine kinases in mammary gland development and
carcinogenesis. Oncogene. 9:1461–1467. 1994.
|
|
8
|
Holder N and Klein R: Eph receptors and
ephrins: effectors of morphogenesis. Development. 126:2033–2044.
1999.
|
|
9
|
Zhang J and Hughes S: Role of the ephrin
and Eph receptor tyrosine kinase families in angiogenesis and
development of the cardiovascular system. J Pathol. 208:453–461.
2006.
|
|
10
|
Lindberg RA and Hunter T: cDNA cloning and
characterization of eck, an epithelial cell receptor
protein-tyrosine kinase in the eph/elk family of protein kinases.
Mol Cell Biol. 10:6316–6324. 1990.
|
|
11
|
Bartley TD, Hunt RW, Welcher AA, et al:
B61 is a ligand for the ECK receptor protein-tyrosine kinase.
Nature. 368:558–560. 1994.
|
|
12
|
Holzman LB, Marks RM and Dixit VM: A novel
immediate-early response gene of endothelium is induced by
cytokines and encodes a secreted protein. Mol Cell Biol.
10:5830–5838. 1990.
|
|
13
|
Walker-Daniels J, Coffman K, Azimi M, et
al: Overexpression of the EphA2 tyrosine kinase in prostate cancer.
Prostate. 41:275–280. 1999.
|
|
14
|
Zelinski DP, Zantek ND, Stewart JC,
Irizarry AR and Kinch MS: EphA2 overexpression causes tumorigenesis
of mammary epithelial cells. Cancer Res. 61:2301–2306. 2001.
|
|
15
|
Kinch MS, Moore MB and Harpole DH Jr:
Predictive value of the EphA2 receptor tyrosine kinase in lung
cancer recurrence and survival. Clin Cancer Res. 9:613–618.
2003.
|
|
16
|
Tandon M, Vemula SV, Sharma A, et al:
EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine
kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth
in a breast cancer mouse model. J Gene Med. 14:77–89. 2012.
|
|
17
|
Wittekind C: 2010 TNM system: on the 7th
edition of TNM classification of malignant tumors. Pathologe.
31:331–332. 2010.(In German).
|
|
18
|
Singh M, Zaino RJ, Filiaci VJ and Leslie
KK: Relationship of estrogen and progesterone receptors to clinical
outcome in metastatic endometrial carcinoma: a Gynecologic Oncology
Group Study. Gynecol Oncol. 106:325–333. 2007.
|
|
19
|
Merritt WM, Lin YG, Han LY, et al: Dicer,
Drosha, and outcomes in patients with ovarian cancer. N Engl J Med.
359:2641–2650. 2008.
|
|
20
|
Hou F, Yuan W, Huang J, et al:
Overexpression of EphA2 correlates with epithelial-mesenchymal
transition-related proteins in gastric cancer and their prognostic
importance for postoperative patients. Med Oncol. 29:2691–2700.
2012.
|
|
21
|
Liu Y, Zhang X, Qiu Y, et al: Clinical
significance of EphA2 expression in squamous-cell carcinoma of the
head and neck. J Cancer Res Clin Oncol. 137:761–769. 2011.
|
|
22
|
Yuan WJ, Ge J, Chen ZK, et al:
Over-expression of EphA2 and EphrinA-1 in human gastric
adenocarcinoma and its prognostic value for postoperative patients.
Dig Dis Sci. 54:2410–2417. 2009.
|
|
23
|
Zantek ND, Walker-Daniels J, Stewart J, et
al: MCF-10A-NeoST: a new cell system for studying cell-ECM and
cell-cell interactions in breast cancer. Clin Cancer Res.
7:3640–3648. 2001.
|
|
24
|
Walker-Daniels J, Riese DJ II and Kinch
MS: c-Cbl-dependent EphA2 protein degradation is induced by ligand
binding. Mol Cancer Res. 1:79–87. 2002.
|
|
25
|
Kinch MS and Carles-Kinch K:
Overexpression and functional alterations of the EphA2 tyrosine
kinase in cancer. Clin Exp Metastasis. 20:59–68. 2003.
|
|
26
|
Holm R, Knopp S, Suo Z, Tropè C and
Nesland JM: Expression of EphA2 and EphrinA-1 in vulvar carcinomas
and its relation to prognosis. J Clin Pathol. 60:1086–1091.
2007.
|
|
27
|
Jia Y, Zeng ZZ, Markwart SM, et al:
Integrin fibronectin receptors in matrix
metalloproteinase-1-dependent invasion by breast cancer and mammary
epithelial cells. Cancer Res. 64:8674–8681. 2004.
|
|
28
|
Fang WB, Ireton RC, Zhuang G, Takahashi T,
Reynolds A and Chen J: Overexpression of EPHA2 receptor
destabilizes adherens junctions via a RhoA-dependent mechanism. J
Cell Sci. 121:358–368. 2008.
|
|
29
|
Brantley-Sieders DM, Zhuang G, Hicks D, et
al: The receptor tyrosine kinase EphA2 promotes mammary
adenocarcinoma tumorigenesis and metastatic progression in mice by
amplifying ErbB2 signaling. J Clin Invest. 118:64–78. 2008.
|
